Pilot of a CGM-Augmented Food Is Medicine Intervention

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity. This study will learn if a FIM intervention (intervention) that includes access to real-time CGM and nutrition counseling can increase engagement, improve glycemic management, and support healthy eating in this population, compared to the FIM intervention alone (comparator). At the study baseline, participants will be randomized to either the intervention or the comparator arm for 16 weeks. The intervention will occur during the first 12 weeks (phase 1: intervention phase) and will be compared to a standard FIM approach without CGM or counseling. Phase 2 (extension phase) will last 4 weeks and will consist of all participants in the intervention and comparator arm receiving both FIM and CGM for self-directed use. The study will also explore participant experiences through a series of semi-structured interviews with a subset of randomly selected participants to identify opportunities for scaling the intervention to a broader population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Able to complete study activities in English

• Aged ≥18 years

• Type 2 diabetes as defined by self-report and confirmed by ICD-10 codes

⁃ Chart review will be conducted by the study team and a diagnosis of type 2 diabetes (E.11.xx) from either the problem list or a diagnosis linked to an encounter will be used as confirmation. Discrepancies in diagnosis codes will be resolved by review of provider notes within the past 3 years.

• HbA1c \> 8.0% in the last 12 months via point of care or venous measurement. If there are multiple values, the most recent one will be considered.

• If taking Glucose-like peptide-1 receptor agonist (GLP-1 RA), it must be stable for at least 1 month prior to enrollment, with no plans to change dose during study period.

• Receiving primary or specialty care within UNC Health as defined by at least one visit with a primary care provider or endocrine provider within the past year

• Indication of a barrier to healthy eating consisting of report of food insecurity (defined as a score greater or equal to 1.0 on the 6-item USDA Food Security Survey Module (FSSM)) and/OR nutrition insecurity (defined as more often than 'Rarely' on the One-Item Gretchen Swanson Nutrition Screener, OR more often than 'Not Very Hard' on the Two-item Nutrition Security Screener (NSS))

⁃ Any positive screen on the FSSM, Gretchen Swanson Nutrition Screener, or NSS

• No plans to move from the area for at least 4 months

• Willing and able to provide written informed consent and participate in all study activities

Locations
United States
North Carolina
University of North Carolina at Chapel Hill
RECRUITING
Chapel Hill
Contact Information
Primary
Penny Wang, MS
penny_wang@med.unc.edu
+1 (919) 843-7720
Backup
Angela Fruik, MPH, RD, LDN
angela.fruik@unc.edu
919-962-6348
Time Frame
Start Date: 2025-09
Estimated Completion Date: 2026-06
Participants
Target number of participants: 60
Treatments
Experimental: Intervention
CGM-Augmented FIM
Active_comparator: Comparator
FIM only
Related Therapeutic Areas
Sponsors
Collaborators: American Heart Association
Leads: University of North Carolina, Chapel Hill

This content was sourced from clinicaltrials.gov